Myriad Genetics Inc. said the phase III POLO study demonstrated its BRACAnalysis CDx test successfully identified patients with metastatic pancreatic cancer who have BRCA mutations and benefitted from treatment with olaparib, a novel PARP inhibitor.
With a growing backlog at NIH and Columbia University’s grants getting canceled over alleged antisemitism, where does that leave NCI-designated cancer centers?
